Anti-inflammative effect of glycyrrhizin on rat thermal injury via inhibition of high-mobility group box 1 protein

Burns

Volumn 41, Issue 2, 2015, Pages 372-378

  Shen, Liangyun ^a   Cui, Ziwei ^a   Lin, Yue ^b   Wang, Shuqin ^b   Zheng, Dongfeng ^b   Tan, Qian ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Burn; Glycyrrhizin; HMGB1; Inflammation

Indexed keywords

BETA ACTIN; GLYCYRRHIZIC ACID; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; ACTIN; ANTIINFLAMMATORY AGENT; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY SURFACE; CONTROLLED STUDY; DRUG MECHANISM; KIDNEY PARENCHYMA; LIVER; LUNG PARENCHYMA; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SKIN INJURY; SKIN PROTECTION; THERMAL INJURY; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BURNS; DISEASE MODEL; INFLAMMATION; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY; LUNG; METABOLISM; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ACTINS; ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; BURNS; DISEASE MODELS, ANIMAL; GLYCYRRHIZIC ACID; HMGB1 PROTEIN; INFLAMMATION; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-1BETA; KIDNEY; LIVER; LUNG; MALE; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84923029635     PISSN: 03054179     EISSN: 18791409     Source Type: Journal    
DOI: 10.1016/j.burns.2014.05.008     Document Type: Article

References (51)

1. Cevik O, Oba R, Macit C, Cetinel S, Kaya OT, Sener E, et al. Lycopene inhibits caspase-3 activity and reduces oxidative organ damage in a rat model of thermal injury. Burns 2012;38:861-71.
2. Piccolo MT, Wang Y, Verbrugge S, Warner RL, Sannomiya P, Piccolo NS, et al. Role of chemotactic factors in neutrophil activation after thermal injury in rats. Inflammation 1999;23:371-85.
3. Huang L, Yao Y, Dong N, Yu Y, He LX, Sheng ZY. Association of high mobility group box-1 protein levels with sepsis and outcome of severely burned patients. Cytokine 2011;53:29-34.
4. Schwacha MG. Macrophages and post-burn immune dysfunction. Burns 2003;29:1-14.
5. Zedler S, Bone RC, Baue AE, von Donnersmarck GH, Faist E. T-cell reactivity and its predictive role in immunosuppression after burns. Crit Care Med 1999;27:66-72.
6. Abdel-Hafez NM, El-Metwally TH. A study on biomarkers, cytokines, and growth factors in children with burn injuries. Ann Burns Fire Disasters 2007;20:89-100.
7. Sheng Z. A brief history of treatment of burn injury in China. Burns Trauma 2013;1:51.
8. Sachse C, Prigge M, Cramer G, Pallua N, Henkel E. Association between reduced human leukocyte antigen (HLA)-DR expression on blood monocytes and increased plasma level of interleukin-10 in patients with severe burns. Clin Chem Lab Med 1999;37:193-8.
9. Shih HC, Su CH, Lee CH. Alternations of surface antigens on leukocy-tes after severe injury: correlation with infectious complications. Intensive Care Med 1998;24:152-6.
10. Pape HC, Remmers D, Grotz M, Schedel I, von Glinski S, Oberbeck R, et al. Levels of antibodies to endotoxin and cytokine release in patients with severe trauma: does posttraumatic dysergy contribute to organ failure? J Trauma 1999;46:907-13.
11. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-54.
12. Seymour CW, Iwashyna TJ, Cooke CR, Hough CL, Martin GS. Marital status and the epidemiology and outcomes of sepsis. Chest 2010;137:1289-96.
13. Li N, Hu X, Liu Y, Wang Y, Wang Y, Liu J, et al. Systemic inflammatory responses and multiple organ dysfunction syndrome following skin burn wound and Pseudomonas aeruginosa infection in mice. Shock 2013;40:152-9.
14. Gamelli RL, He LK, Liu LH. Macrophage mediated suppression of granulocyte and macrophage growth after burn wound infection reversal by means of anti-PGE2. J Burn Care Rehabil 2000;21:64-9.
15. Gong G, Yuan LB, Hu L, Wu W, Yin L, Hou JL, et al. Glycyrrhizin attenuates rat ischemic spinal cord injury by suppressing inflammatory cytokines and HMGB1. Acta Pharmacol Sin 2012;33:11-8.
16. Bustin M. Revised nomenclature for high mobility group (HMG) chromosomal proteins. Trends Biochem Sci 2001;26:152-3.
17. Li J, Kokkola R, Tabibzadeh S, Yang R, Ochani M, Qiang X, et al. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med 2003;9:37-45.
18. Yang H, Antoine DJ, Andersson U, Tracey KJ. The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol 2013;93:865-73.
19. Alleva LM, Budd AC, Clark IA. Systemic release of high mobility group box 1 protein during severe murine influenza. J Immunol 2008;181:1454-9.
20. Chen LC, Yeh TM, Wu HN, Lin YY, Shyu HW. Dengue virus infection induces passive release of high mobility group box 1 protein by epithelial cells. J Infect 2008;56:143-50.
21. Chu JJ, Ng ML. The mechanism of cell death during West Nile virus infection is dependent on initial infectious dose. J Gen Virol 2003;84:3305-14.
22. Joseph T, Cepica A, Brown L, Ikede BO, Kibenge FS. Mechanism of cell death during infectious salmon anemia virus infection is cell type-specific. J Gen Virol 2004;85:3027-36.
23. Grover A, Taylor J, Troudt J, Keyser A, Sommersted K, Schenkel A, et al. Mycobacterial infection induces the secretion of high-mobility group box 1 protein. Cell Microbiol 2008;10:1390-404.
24. Hofner P, Seprenyi G, Miczak A, Buzas K, Gyulai Z, Medzihradszky KF, et al. High mobility group box 1 protein induction by Mycobacterium bovis BCG. Mediators Inflamm 2007;2007:53805.
25. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-51.
26. Monder C, Stewart PM, Lakshmi V, Valentino R, Burt D, Edwards CR. Licorice inhibits corticosteroid 11 betadehydrogenase of rat kidney and liver: in vivo and in vitro studies. Endocrinology 1989;125:1046-53.
27. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997;79:1494-500.
28. van Rossum TG, Vulto AG, Hop WC, Schalm SW. Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol 2001;96:2432-7.
29. Yamamura Y, Kotaki H, Tanaka N, Aikawa T, Sawada Y, Iga T. The pharmacokinetics of glycyrrhizin and its restorative effect on hepatic function in patients with chronic hepatitis and in chronically carbon-tetrachloride- intoxicated rats. Biopharm Drug Dispos 1997;18:717-25.
30. Negi AS, Kumar JK, Luqman S, Shanker K, Gupta MM, Khanuja SP. Recent advances in plant hepatoprotectives: a chemical and biological profile of some important leads. Med Res Rev 2008;28(5):746-72.
31. Sitia G, Iannacone M, Muller S, Bianchi ME, Guidotti LG. Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol 2007;81:100-7.
32. Zhai CL, Zhang MQ, Zhang Y, Xu HX, Wang JM, An GP, et al. Glycyrrhizin protects rat heart against ischemiareperfusion injury through blockade of HMGB1-dependent phospho-JNK/Bax pathway. Acta Pharmacol Sin 2012;33:1477-87.
33. Bader A, Ebert S, Giri S, Kremer M, Liu S, Nerlich A, et al. Skin regeneration with conical and hair follicle structure of deep second-degree scalding injuries via combined expression of the EPO receptor and beta common receptor by local subcutaneous injection of nanosized rhEPO. Int J Nanomedicine 2012;7:1227-37.
34. Yamamura Y, Santa T, Kotaki H, Uchino K, Sawada Y, Iga T. Administration-route dependency of absorption of glycyrrhizin in rats: intraperitoneal administration dramatically enhanced bioavailability. Biol Pharm Bull 1995;18:337-41.
35. Rouhiainen A, Imai S, Rauvala H, Parkkinen J. Occurrence of amphoterin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation. Thromb Haemost 2000;84:1087-94.
36. Peng DZ. Researches in immunological responses after burn injury in China. Zhonghua Shao Shang Za Zhi 2008;24:390-2.
37. Li Y, Ge S, Peng Y, Chen X. Inflammation and cardiac dysfunction during sepsis, muscular dystrophy, and myocarditis. Burns Trauma 2013;1:109.
38. Ravat F, Payre J, Peslages P, Fontaine M, Sens N. Burn: an inflammatory process. Pathol Biol (Paris) 2011;59:63-72.
39. Evers LH, Bhavsar D, Mailänder P. The biology of burn injury. Exp Dermatol 2010;19:777-83.
40. Toth B, Alexander M, Daniel TJ, Chaudry IH, Hubbard WJ, Schwacha MG. The role of gd T cells in the regulation of neutrophil-mediated tissue damage after thermal injury. J Leukoc Biol 2004;76:545-52.
41. Youn YK, LaLonde C, Demling R. The role of mediators in the response to thermal injury. World J Surg 1992;16:30-6.
42. Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 1999;19:5237-46.
43. Bianchi ME. HMGB1 loves company. J Leukoc Biol 2009;86:573-6.
44. Boone BA, Lotze MT. Targeting damage-associated molecular pattern molecules (DAMPs) and DAMP receptors in melanoma. Methods Mol Biol 2014;1102:537-52.
45. Rubartelli A, Lotze MT. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol 2007;28:429-36.
46. Yang R, Harada T, Mollen KP, Prince JM, Levy RM, Englert JA, et al. Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Mol Med 2006;12:105-14.
47. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011;29:139-62.
48. Krysko O, Love Aaes T, Bachert C, Vandenabeele P, Krysko DV. Many faces of DAMPs in cancer therapy. Cell Death Dis 2013;4:e631.
49. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005;5:331-42.
50. Fink MP. Ethyl pyruvate: a novel treatment for sepsis. Curr Drug Targets 2007;8:515-8.
51. Mollica L, De Marchis F, Spitaleri A, Dallacosta C, Pennacchini D, Zamai M, et al. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol 2007;14:431-41.